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NKG2D is an activating receptor expressed by NK and T cells primarily involved in the
elimination of transformed and infected cells. NKG2D ligands are self-proteins restrictedly
expressed in healthy tissues, but induced in response to signaling pathways commonly
associated with transformation. Proliferative, tumor suppressor, and stress signaling path-
ways linked to the tumorigenic process induce the expression of NKG2D ligands, initiating
an immune response against the incipient tumor. Nevertheless, the activity of NKG2D lig-
ands is counter-regulated in vivo by the immunoediting of cancer cells, resulting in the
expression of multiple mechanisms of immune evasion in advanced tumors. The redun-
dancy of NKG2D ligands, besides increasing the complexity of their regulation, may impair
the generation of these immune evasion mechanisms. In this review, we attempt to inte-
grate the mechanisms and pathways involved in the regulation of NKG2D ligand expression
in cancer.
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HUMAN NKG2D AND ITS LIGANDS
NKG2D is a type-II transmembrane-anchored glycoprotein con-
stitutively expressed on the surface of NK, CD8 T, and γδ T cells
(1). At the cell membrane, human NKG2D associates with DAP10,
while mouse NKG2D may associate with both DAP10 and DAP12,
which activate downstream signaling pathways resulting in the
activation of NK cells and co-stimulation of CD8 T cells (2). Cross-
linking of NKG2D receptor alone on freshly isolated NK cells does
not seem to trigger a significant cell-mediated cytotoxic response;
and simultaneous cross-linking of other activating receptors or
stimulation of NK cells with IL-15 or high dose of IL-2 is rather
necessary to kill tumor target cells (3).
NKG2D is a receptor for multiple ligands (NKG2DLs), which
are distant members of the MHC class I family. In humans,NKG2D
is a receptor for MICA and MICB (MICA/B) and ULBP1–6 mol-
ecules (4–8) (Figure 1). NKG2DLs are restrictedly expressed in
healthy cells avoiding autoimmunity, but they are frequently over-
expressed in infected and transformed cells, acting as a danger
signal that favors the perforin-mediated elimination of trans-
formed cells, thus acting as an extrinsic mechanism of cancer
surveillance that complements the intrinsic processes that control
growth and proliferation of tumor cells.
NKG2D IS INVOLVED IN THE IMMUNE SURVEILLANCE OF
CANCERS
NKG2D-deficient mice are more prone to develop cancer (9),
and neutralization of NKG2D increases the sensitivity of mice
to carcinogen-induced sarcomas (10). Conversely, murine NK
cells may efficiently eliminate cancer cells expressing NKG2DLs
in vivo, highlighting the relevant role of this receptor in the can-
cer immune surveillance in mice (11–13). In humans, NKG2DLs
are restrictedly expressed in healthy cells, but a broad expression
of these proteins is observed in transformed cells, rendering them
more susceptible to NK cell-mediated killing (1, 14–16). Moreover,
cell-associated NKG2DL expression correlates with the outcome
in colorectal (16, 17), breast, (18) and pancreatic cancers (19) and
hepatocellular carcinoma (20). However, it is noteworthy that high
expression of ULBP2 and ULBP4 has been paradoxically associ-
ated with poor prognosis in ovarian cancer, and it does not appear
to be related to an increase of the shedding of these molecules
(21, 22). Further, the development of immune evasion mecha-
nisms by cancer cells has been associated with poor prognosis in
different types of cancer (see below). Thus, the serum level of
soluble MICA (sMICA) is an independent prognostic factor for
multiple myeloma (23) and advanced hepatocellular carcinoma
(24). sMICA and soluble MICB (sMICB) serum levels were cor-
related with disease stage and survival rates in oral squamous
cell carcinoma patients (25), whereas soluble ULBP2 (sULBP2)
was associated with poor prognosis in melanoma (26), chronic
lymphocytic leukemia (27), and lung cancer (28).
Albeit these data clearly indicate an important role for the
NKG2D response in the immune surveillance of human can-
cers, the molecular bases underlying the regulation of NKG2DL
expression have not been fully elucidated. Nevertheless, increasing
evidence indicates that the activation of oncogenic pathways com-
monly associated with the tumorigenic process may be responsible
for the induction of NKG2DL expression and the activation of the
NKG2D response (29) (Table 1).
DNA DAMAGE AND NKG2D RESPONSE
DNA damage potentially represents an initiating event for carcino-
genesis as it is frequently observed in precancerous lesions. As a
result of the DNA damage response (DDR), cell cycle checkpoints
are activated, stopping the cell cycle to give the cell time to repair
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the damage, and, if such damage is too great, to trigger apoptosis.
DNA damage checkpoint activation is controlled by two kinases:
ATM (ataxia telangiectasia, mutated), which responds to DNA
double-strand breaks and disruptions in chromatin structure;
and ATR (ATM- and Rad3-related), which primarily responds to
stalled replication forks. Activated ATM or ATR initiates a pro-
tein kinase cascade that includes the activation of the checkpoint
kinases CHK1 and CHK2, and p53. In a seminal paper, it was
shown that DNA damage also activates the immune response as an
additional extrinsic control mechanism that favors the elimination
of damaged and cancer cells through the induction of NKG2DL
expression (30). It is worth-mentioning that the up-regulation of
NKG2DLs occurs, at least in mice, in a p53-independent man-
ner, which is particularly relevant given that a p53 expression is
lost in a majority of clinical aggressive and invasive cancers. How-
ever, the downstream regulators of the DDR involved in NKG2DL
expression remain ill-defined.
FIGURE 1 | Biochemical and structural properties of human and mouse
NKG2D ligands. TM, transmembrane; GPI, glycosylphosphatidylinositol.
DNA damage response is activated in response to ionizing
radiation and chemotherapy. Consequently, the immune response
may contribute to the efficacy of these conventional cancer treat-
ments. Many viruses with distinct replication strategies, such as
DNA viruses and retroviruses, may also activate the DDR, which
may potentially activate the NKG2D response. The replication of
viral DNA in the nucleus has the potential to trigger the DDR if
the ends of viral genomes are exposed and recognized as double
stranded breaks. Retroviral DNA integration creates a discontinu-
ity in the host cell chromatin, also activating the DDR. Likewise,
induction of NKG2DLs by two retroviral infections, caused by
Abelson murine leukemia virus and human immunodeficiency
virus (HIV), supports a role of DDR in the NKG2D-mediated
anti-viral response (48, 49). A more universal role of this pathway
in the elimination of virus-infected cells remains to be established.
NKG2DL expression may also be induced as a result of DNA
replication stress and activation of ATM/ATR in human T cells
that proliferate in response to mitogens, antigens, and superanti-
gens (50). This has been proposed to limit undesired immune
responses; however, the underlying mechanisms and the biologi-
cal significance of NKG2DL expression in T cells and other healthy
cells are poorly understood.
OTHER TYPES OF CELLULAR STRESS REGULATE NKG2D
RESPONSE
Different forms of cellular stress frequently associated with the
tumorigenic process are involved in the regulation of NKG2DL
expression. Early reports showed that heat shock was able to induce
MICA and MICB expression (32). This induction of MICA/B
transcription was lately described as the result of the binding
of heat shock factor 1 (HSF1) to the promoters of MICA and
MICB genes (33). Several studies showed that oxidative stress also
induced MICA/B gene and protein expression in several tumor
cell lines (34, 51). In normal human bronchial epithelial cells,
oxidative stress induced MICA and ULBPs expression through the
Table 1 | Main signaling pathways that regulate NKG2D ligand expression.
Signaling pathway Cell model NKG2D ligand Reference
STRESS PATHWAYS
DNA damage response Non-tumor cell lines Mouse and human ligands (30)
Myeloma (31)
Thermal stress Epithelial cell lines MICA/B (32, 33)
Oxidative stress Epithelial cell lines/epithelial bronchial cells MICA/B, ULBP1–4 (34, 35)
PROLIFERATIVE/ONCOGENE PATHWAYS
c-Myc Primary lymphoma Rae-1ε (36)
H-RasV12 Mice and human cell lines Rae-1α Rae-1β, ULBP1–3 (37)
HER2/HER3 Breast cancer cell lines MICA/B (38)
BCR–ABL CML cells MICA/B (39–41)
PI3K Multiple Mouse and human ligands (37, 38, 42, 43)
TUMOR SUPPRESSOR PATHWAYS
P53 Epithelial cell lines ULBP1,2 (44–46)
TUMOR PROGRESSIONAND METASTASIS
EMT Epithelial cell lines MICA/B, ULBP1–3 (47)
CML, chronic myelogenous leukemia; EMT, epithelial-to-mesenchymal transition.
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activation of ERK (35). Hypoxia has also been shown to down-
regulate the surface expression of MICA in osteosarcoma cell lines
through the induction of hypoxia-inducible factor 1α (HIF-1α),
but independently of nitric oxide (NO) production (52).
PROLIFERATIVE SIGNALS INDUCE NKG2D RESPONSE
Early reports showed that MICA/B mRNA and protein expres-
sion are mostly limited to proliferating epithelial cells, but they are
scarcely expressed in quiescent cells (32, 33, 50). Recently, prolif-
eration has been associated with the induction of the expression
of murine RAE-1 family of NKG2DLs in mouse fibroblasts, and
of MICA/B and ULBP2 in HCT116 colorectal cancer cells (42).
The induction of NKG2DL expression was independent of stress
pathways. Instead, Raet1 genes, but not MULT1 and H60b, were
found to be direct targets of E2F family of transcription factors,
which plays a major role during the G1/S transition and cell cycle
reentry. This provides a mechanistic link between proliferation
and NKG2D response. Moreover, murine RAE-1ε induction in
primary fibroblast cultures was blocked by inhibiting prolifera-
tive pathways such as cyclin-dependent kinases, PI3K–mTOR, and
MAPK pathways (42).
Unrestrained proliferation is a common characteristic of can-
cer cells. Albeit it has not always been mechanistically linked to
cell proliferation, it has been reported that inappropriate over-
expression of several oncogenes induced NKG2DL expression
independently of DDR. However, the expression of certain onco-
genes (K-ras and c-myc or Akt and c-myc) was not sufficient to
induce NKG2DL expression in primary ovarian epithelial cells
(30). This probably reflects that transformation is a multistep
process, and changes in many pathways, such as tumor suppres-
sor pathways, are required for both transforming a normal cell
into a cancer cell and for activating the NKG2D response. In fact,
it has been reported that several oncogenic pathways up-regulate
NKG2DLs. For instance, NKG2DLs are induced on spontaneously
arising tumors in an Eµ-myc murine model of lymphoma (36).
The induction of NKG2DLs involves the activity of c-Myc, which
is a master regulator of proliferation. Similarly, the oncogenic H-
RasV12 protein up-regulates the expression of Rae-1α and Rae-1β
in mouse and of ULBP1–3 in human cells (37). H-RasV12 mainly
regulated the expression of Rae-1 by post-transcriptional mecha-
nisms via Raf–MAPK/MEK and PI3K pathways. Ras signals also
contribute to the induction of NKG2DL expression in primary
fibroblast cultures in response to the serum, which may be blocked
by epidermal growth factor receptor (EGFR) inhibitors (37). EGFR
comprises a family of four closely related transmembrane tyro-
sine kinase receptors (also known as HER1–4). Amplification
or over-expression of the HER2/HER3 dimer is involved in the
progression of different cancers, particularly in certain types of
aggressive breast cancer. It has been shown that over-expression of
HER2/HER3 activates the expression of MICA/B, mainly through
the PI3K/AKT pathway (38). Philadelphia chromosome is a spe-
cific chromosomal translocation associated with chronic myel-
ogenous leukemia (CML). It results in BCR–ABL fusion protein,
with a continuously activated tyrosine kinase activity, thus pro-
moting the unrestrained cell division of leukemia cells. BCR–ABL
kinase activity was also linked to NKG2DL expression and the
activity of NK cells (39, 40). Thus, BCR/ABL induces the MICA
surface expression on CML leukemia cells, whereas it was absent
on healthy hematopoietic cells (41).
Induction of host cell proliferation is a common viral strat-
egy that favors viral survival and replication. However, it may also
induce NKG2DL expression, resulting in an NKG2D-dependent
elimination of the infected cell. Thus, the activation of PI3K path-
way by the murine cytomegalovirus results in the expression of
RAE-1 family of NKG2DLs (43). Similarly, adenovirus serotype
5 (Ad5) E1A oncogene up-regulates RAE-1 expression, but not
murine ULBP-like transcript 1 (53).
Overall, these data suggest that proliferative signals gener-
ated by oncogene activation and virus infection and, possibly by
other physiological situations, may alert the immune surveillance
response through the induction of the NKG2D response.
TUMOR SUPPRESSION AND SENESCENCE MAY INDUCE
NKG2DL EXPRESSION
The deregulation of the activity of oncogene proteins is counter-
regulated by tumor suppressor proteins. These proteins repress
cellular proliferation and the loss of their function is an additional
characteristic associated with tumorigenesis. For instance, in the
Eµ-myc murine model of lymphoma, sustained over-expression
of Myc signaling induces p19Arf expression, resulting in apop-
tosis through the inhibition of Mdm2 and stabilization of the
p53 tumor suppressor protein. Thus, a combination of deregu-
lated activity of Myc and the loss of a tumor suppressor protein
(either p19Arf or p53) is involved in both tumor progression and in
the induction of Rae-1 in lymphoma cells (36). Thus, despite the
existence of few experimental data, the current knowledge about
tumor biology suggests that the combination of oncogenes and
tumor suppressors may be involved in the regulation of NKG2DL
expression.
Accordingly, the tumor suppressor p53 has been associated with
the regulation of NKG2D response. Over-expression of wild-type
p53 in cancer cell lines strongly up-regulated the expression of
ULBP1 and ULBP2, but not of other NKG2DLs, upon binding of
p53 to response elements located in the intronic regions of these
genes (44, 45). Moreover, the small molecule inhibitor Nutlin-3a
decreased ULBP2 levels in a p53-dependent manner, through the
increase in cellular levels of the suppressive miR-34 (46).
Additionally to growth arrest and apoptosis, p53 may induce
senescence in response to diverse forms of cellular stress, including
telomere shortening, DNA damage, oncogene activation, oxidative
stress, and chemotherapeutic drug administration. The senescence
program activates p53 and p16INK4a–pRb tumor suppressor path-
ways, which establish an irreversible form of cell cycle arrest. The
most fully described function of senescence in vivo is the abil-
ity to establish a potent barrier to tumorigenesis in response to
oncogene activation or DNA damage. A typical characteristic of
senescent cells, known as “senescence-associated secretory pheno-
type,” is the secretion of inflammatory cytokines and chemokines
that may recruit and activate distinct adaptive and innate immune
cells subsets, including NK and T cells.
It has been shown that chemotherapeutic drug treatment of
myeloma cells induces DDRs and activates the expression of
NKG2DLs, mainly in senescent cells, resulting in their elimina-
tion by NK cells through the recognition by NKG2D and DNAM-1
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receptors (31). NKG2DLs are also up-regulated on activated senes-
cent hepatic stellate cells (54). Further, a recent study in a mouse
model of senescence generated by induction of p53 expression also
showed that NK cells participate in the elimination of senescent
cells in an NKG2D-dependent manner (55). Nevertheless, induc-
tion of p53 did not increase NKG2DL expression, but, instead,
induced senescent cell to secrete chemokines that recruit NK cells.
NKG2DL EXPRESSION DURING TUMOR PROGRESSION
It has been well established that NKG2D may protect the host
from tumor initiation (9–13); however, less information exists
regarding the role of NKG2D in tumor progression and metas-
tasis. Early reports showed the loss of MICA/B expression in
metastatic melanoma suggesting the immune selection of MICA/B
negative tumors (56). Similarly, we have recently reported that
epithelial-to-mesenchymal transition (EMT) is an immunological
checkpoint that controls tumor progression through NKG2D-
mediated immune responses (47, 57). EMT is one of the first steps
of the metastatic cascade, which results in the loss of epithelial
characteristics and the gain of mesenchymal properties by malig-
nant cells, such as migration and invasiveness. EMT induction by
Snail1 over-expression, GSK-3 inhibition, or TGF-β stimulation
up-regulated NKG2DL expression in epithelial cells, rendering
EMT cells more susceptible to NK cell-mediated killing. Sp1 and
Sp3 transcription factors are key regulators of the basal transcrip-
tion of MICA/B and ULBP1–3 (33, 58, 59); and induction of Sp1
activity in colorectal tumor cells was involved in the up-regulation
of NKG2DL expression during the EMT process. In vivo, MICA/B
and ULBP1 proteins are expressed in healthy colon mucosa cells,
displaying a polarized apical distribution; and no interaction
with NKG2D-bearing immune cells was observed (47, 57). The
polarized expression of MICA and ULBP1 was also observed in
malignant cells retaining epithelial characteristics, whereas a loss
of the polarization of NKG2DL expression was observed in malig-
nant cells that suffer EMT. Moreover, a dramatic increase in the
number of NKG2D-bearing tumor-infiltrating T lymphocytes was
observed in specimens lacking MICA expression, suggesting that
the loss of the epithelial integrity and polarity, characteristics of the
EMT process, may allow the diffusion of MICA/B proteins along
the membrane of mesenchymal cells, resulting in their elimina-
tion by NKG2D-bearing immune cells. Overall, these data suggest
that tumor progression and metastasis, a key characteristic of
malignant cancers, may also be under the control of the NKG2D
response.
TUMOR EVASION OF NKG2D RESPONSE
NKG2D-deficient mice expressed higher amounts of NKG2DLs
in cancer cells than similar tumors in wild-type mice, which sug-
gests that NKG2DL expression in a host may be counter-regulated
by the immunoediting of cancer cells (9). This is in agreement
with the description of a plethora of immune evasion mecha-
nisms that impair the NKG2D-mediated response. Repression of
NKG2DL expression is frequently observed in advanced tumors
and metastases compared with primary tumors, and this may be
regulated by epigenetic mechanisms. In advanced tumors, histone
deacetylases (HDACs) may interact with the promoter region of
NKG2DL genes, regulating the chromatin structure and impair-
ing the access of transcription factors to their promoters. Thus,
HDAC1 may inhibit the transcription of MICA/B on leukemia cells
(60), whereas HDAC3 may repress the transcription of ULBP1–3
in epithelial tumors (59). Consequently, HDAC inhibitors stim-
ulate the expression of NKG2DLs on tumor cells (60–63). Other
mechanisms, such as the over-expression of suppressive microR-
NAs in tumors, may also account for the repression of NKG2DL
expression (46, 64–66). Contrarily, sustained NKG2DL expression
and prolonged interaction with NKG2D receptor also leads to a
strong down-regulation of NK cell cytotoxic activity (67, 68).
NKG2DLs may be also shed as soluble proteins (69, 70), which
may cause the endocytosis and degradation of NKG2D recep-
tor in immune cells (2). Interaction of MICA on the surface of
tumor cells with the chaperon molecule ERp5 plays a relevant
role in sMICA shedding (71). ERp5 may form a transitory disul-
fide bond with MICA, which induces a conformational change,
allowing the proteolytic cleavage of MICA by proteases. Likewise,
membrane ERp5 was functionally associated with sMICA shed-
ding in chronic lymphocytic leukemia patients (72); and sMICA
serum levels have been associated with ERp5 expression in mul-
tiple myeloma (73) and Hodgkin lymphoma (74). sULBP2 may
also be released from tumor cells by proteolytic cleavage (75).
However, engagement of sULBP2 not necessarily down-regulates
NKG2D receptor. sULBP4 may be shed from tumor cells by alter-
native splicing mechanisms (76). Additionally, cancer cells may
release MICA, MICB, and ULBPs into exosomes (77, 78). This
event appears to be ligand-dependent, since ULBP2 is mainly
shed by metalloproteinases, whereas ULBP3 is abundantly released
as part of exosomes. Moreover, in the case of MICA, it may be
allele-dependent (79). Exosomes containing NKG2DLs selectively
down-regulate NKG2D expression on CD8 T and NK cells.
CONCLUDING REMARKS
As discussed above, relevant biological pathways associated with
tumorigenesis, including proliferative, tumor suppressor, and
stress pathways, are key signals involved in the induction of the
NKG2D response in cancer. Many of these pathways are frequently
activated in viral infections and in other pathological and phys-
iological situations, providing a common link in the regulation
of NKG2DLs between these pathologies and cancer. Nevertheless,
little information regarding to the regulation of NKG2DLs in non-
cancer-conditions is available, and future research in this field is
needed.
However, the activity of NKG2DLs is counter-regulated in vivo
by the immunoediting of cancer cells and for the development of
immune evasion mechanisms in virus. Likewise, advanced tumors
develop multiple mechanisms of immune evasion that frequently
modify NKG2DL expression, thus making difficult to differentiate
the intrinsic mechanisms of NKG2DL regulation from the con-
sequences of the immune selection. As described above, distinct
NKG2DLs are differentially regulated by specific oncogenic path-
ways. Thus, the redundancy of NKG2DLs presumably increases
the range of different pathological situations in which NKG2D
response may be activated and may also impair the generation of
immune evasion mechanisms.
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